Parkinson's Disease

Conditions We Treat

Parkinson’s is a progressive neurological condition for which there is currently no cure — but with appropriate support, most people manage their symptoms effectively and maintain meaningful quality of life.

Investigational — rTMS

rTMS for Parkinson’s disease is investigational in Australia. It is not TGA-approved for this indication and is not Medicare-funded. It is offered under specialist oversight with full informed consent as part of an individualised treatment plan. For referring clinicians: detailed scientific literature available on request at info@brainaidclinics.com.

Understanding the condition

What is Parkinson's disease?

Parkinson’s disease is a progressive neurological condition that occurs when the dopamine-producing nerve cells of the substantia nigra — a region of the brain responsible for smooth, coordinated movement — gradually degenerate. As dopamine levels decline, the motor system becomes progressively impaired.

The condition affects more than 150,000 Australians and is most common in older adults, though younger-onset Parkinson’s does occur. The cause is not fully understood — a combination of genetic predisposition, environmental factors, and age-related neurodegeneration contributes in most cases.

There is currently no cure. With appropriate medical management and supportive care, many people live well with Parkinson’s for many years.

Symptoms — motor and non-motor

Tremor — typically resting tremor, often beginning on one side of the body

Rigidity and bradykinesia — muscle stiffness and slowness of movement

Postural instability — balance and coordination difficulties

Non-motor symptoms — fatigue, sleep disturbance, mood changes, cognitive difficulties

Speech and swallowing changes — reduced volume, monotone speech, or swallowing difficulties in later stages

Standard of care

How Parkinson's disease is typically managed

01 Medication

Levodopa remains the most effective medication for motor symptoms, increasing dopamine availability or mimicking its effects. Dopamine agonists, MAO-B inhibitors, and other agents are used individually or in combination, adjusted over time as the condition progresses. Medication management is led by your neurologist.

02 Physiotherapy and exercise

Regular physical activity is one of the most robustly evidence-supported interventions in Parkinson’s — improving mobility, balance, strength, and quality of life. Physiotherapy supports gait, posture, and fall prevention. Exercise also has direct neuroprotective effects, upregulating BDNF and supporting the dopaminergic system.

03 Occupational and speech therapy

Occupational therapy supports adaptation of daily activities and home environment. Speech therapy — including the LSVT LOUD programme — addresses voice volume and swallowing. Both are important components of maintaining independence and quality of life.

04 Deep brain stimulation

DBS involves implanting electrodes in specific brain regions to regulate abnormal electrical signals. It is effective for carefully selected patients — typically those with significant motor fluctuations or medication-related complications — but is appropriate for fewer than 10% of patients. Neurosurgical assessment is required.

Investigational neuromodulation

rTMS for Parkinson's disease

Repetitive TMS is being explored as a non-invasive adjunct for Parkinson’s disease. Magnetic pulses targeted to the motor cortex and supplementary motor area can modulate the cortical excitability changes associated with dopamine depletion. Some studies report modest improvements in motor symptoms — including rigidity and bradykinesia — and non-motor symptoms including mood and cognitive function.

rTMS for Parkinson’s is investigational in Australia. It is not TGA-approved for this indication, is not Medicare-funded, and should not be considered a replacement for established treatments. It may be considered as part of an individualised plan in specialist consultation — particularly for patients managing non-motor symptoms alongside medication-related fluctuations, or where depression is a significant comorbidity.

Referring clinicians seeking a detailed scientific literature review of rTMS for Parkinson’s disease can contact our team at info@brainaidclinics.com.

When rTMS may be discussed

Comorbid depression

Depression affects up to 50% of people with Parkinson’s. Where it meets criteria for treatment-resistant depression, rTMS is TGA-approved and Medicare rebates apply.

Cognitive and non-motor symptoms

Fatigue, cognitive slowing, and mood symptoms that do not respond adequately to medication adjustment may benefit from prefrontal rTMS in selected patients.

Motor symptom adjunct

Investigational motor cortex rTMS as an adjunct to medication — discussed individually and only in specialist consultation, with realistic expectations clearly established.

rTMS for Parkinson’s is investigational. Not TGA-approved for this indication. Not Medicare-funded. Offered under specialist oversight with full informed consent. Individual outcomes vary.

Common Questions

What patients ask us

Is there a cure for Parkinson's disease?

Parkinson’s disease is not currently curable, but symptoms can often be effectively managed through medication, lifestyle interventions, and supportive therapies. Research into disease-modifying treatments is active. With appropriate management, many people live well with Parkinson’s for many years after diagnosis.

What non-medication treatments are available?

Physiotherapy, occupational therapy, and speech therapy are standard components of Parkinson’s management. Regular exercise — particularly aerobic activity — has robust evidence for improving mobility, balance, and quality of life, and may have neuroprotective effects. Psychological support addresses mood symptoms. Nutritional guidance supports overall wellbeing. For carefully selected patients, deep brain stimulation is an advanced surgical option. rTMS is investigational and discussed individually in specialist consultation.

Is rTMS approved for Parkinson's disease in Australia?

No. rTMS is not TGA-approved for Parkinson’s disease in Australia, and there is no Medicare rebate for this application. The evidence base is promising but preliminary — showing potential benefits for some motor and non-motor symptoms in selected patients — and ongoing research is needed. Where it is considered, it is offered as an investigational treatment in specialist consultation, with outcomes, evidence limitations, and costs discussed fully and clearly. It should never replace established medication management led by your neurologist.

Does Brain Aid Clinics treat comorbid depression in Parkinson's?

Yes. Depression affects up to 50% of people with Parkinson’s and significantly impacts quality of life. Where depression meets clinical criteria for treatment-resistant depression — inadequate response to two or more antidepressant trials — rTMS is TGA-approved and Medicare rebates apply (MBS 14216, MBS 14217). This is a distinct and well-supported indication, separate from the investigational use of rTMS for motor symptoms of Parkinson’s.

Clinical and regulatory note: rTMS for Parkinson’s disease is investigational in Australia and is not TGA-approved or Medicare-funded for this indication. All information is for general informational purposes and does not constitute medical advice. Treatment decisions require specialist consultation. Brain Aid Clinics operates within AHPRA-compliant clinical and regulatory boundaries with full informed consent at every stage. ABN 76 664 676 420.

0466 352 811

Conditions We Treat